AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18515805 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endurance-resistance training (CT)
Number of subjects: 58
Study 18515805 — intervention group
Group type: COMPARATOR
Intervention: Endurance training (ET)
Number of subjects: 58
Study 17073812 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose human ALB (albumin) therapy
Number of subjects: 1800
Study 17073812 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 1800
Study 14618048 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic fat pad removal
Number of subjects: 320
Study 14618048 — intervention group
Group type: COMPARATOR
Intervention: Aortic fat pad intact
Number of subjects: 320
Study 14618048 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of atrial arrhythmias
Number of subjects: 320
Study 14618048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat pad status in extension study
Number of subjects: 320
Study 10745855 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-cell pulsating dynamic mattress system
Number of subjects: 198
Study 10745855 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 198
Study 9373421 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist in-patient (DDU)
Number of subjects: 186
Study 9373421 — intervention group
Group type: COMPARATOR
Intervention: General psychiatric (GEN)
Number of subjects: 186
Study 9373421 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for ex-DDU patients
Number of subjects: 186
Study 9373421 — intervention group
Group type: COMPARATOR
Intervention: Follow-up for ex-GEN patients
Number of subjects: 186
Study 8336224 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (.35 mg/kg)
Number of subjects: 90
Study 8336224 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (.70 mg/kg)
Number of subjects: 90
Study 8336224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 8336224 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Midazolam, Diazepam, Placebo)
Number of subjects: 90
Study 3534348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (IV 16 mg 1/2 hr before and 8 mg at 1 1/2, 3 1/2, and 5 1/2 hr after cisplatin)
Number of subjects: 52
Study 3534348 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (IV 2 mg/kg 1/2 hr before and 1 1/2, 3 1/2, and 5 1/2 hr after cisplatin)
Number of subjects: 52
Study 3534348 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide plus Dexamethasone
Number of subjects: 52
Study 3534348 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide alone
Number of subjects: 52
Study 3534348 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metoclopramide and dexamethasone
Number of subjects: 52
Study 3534348 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response to antiemetic agents
Number of subjects: 52
Study 31427072 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient code status (do-not-resuscitate or do-not-intubate)
Number of subjects: 194
Study 29590698 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised cooling and compression therapy with the Cryo/Cuff™‐system (3 × 10 min twice daily)
Number of subjects: 50
Study 29590698 — intervention group
Group type: COMPARATOR
Intervention: Conventional cooling therapy
Number of subjects: 50
Study 26928670 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg/day
Number of subjects: 125
Study 26928670 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 800 mg/day
Number of subjects: 125
Study 26928670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 24572997 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg intravenously over 2 hours)
Number of subjects: 196
Study 24572997 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline 5 mL/kg intravenously)
Number of subjects: 196
Study 22650326 — intervention group
Group type: COMPARATOR
Intervention: Nemonoxacin 125 mg
Number of subjects: 36
Study 22650326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 250 mg
Number of subjects: 36
Study 22650326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg
Number of subjects: 36
Study 22650326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 750 mg
Number of subjects: 36
Study 22650326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg (multiple doses)
Number of subjects: 36
Study 22650326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg (fed conditions)
Number of subjects: 36
Study 20306554 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 200, 400, or 600 mg b.i.d. plus optimized background therapy
Number of subjects: 178
Study 20306554 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d. plus optimized background therapy
Number of subjects: 178
Study 18310400 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0
Study 18310400 — intervention group
Group type: EXPERIMENTAL
Intervention: Carefully selected pharmacological therapy
Number of subjects: 0
Study 18310400 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological history and coping mechanisms understanding
Number of subjects: 0
Study 16322138 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start program (home visitation)
Number of subjects: 443
Study 12588019 — intervention group
Group type: EXPERIMENTAL
Intervention: 2TU PPD prepared by the Guindy laboratory (Dilution-G)
Number of subjects: 1525
Study 12588019 — intervention group
Group type: EXPERIMENTAL
Intervention: 2TU PPD prepared by the SSI (Dilution-S)
Number of subjects: 1525
Study 12588019 — intervention group
Group type: EXPERIMENTAL
Intervention: 1TU and 2TU Dilution-G
Number of subjects: 1525
Study 12588019 — intervention group
Group type: COMPARATOR
Intervention: 1TU PPD RT23 with Tween 80
Number of subjects: 1525
Study 10583708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Mg load with 0.1 mmol Mg-aspartate hydrochloride per kilogram bodyweight for 1 hour.
Number of subjects: 34
Study 10583708 — intervention group
Group type: COMPARATOR
Intervention: Placebo group receiving no Mg medication.
Number of subjects: 34
Study 10583708 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Mg values measured by atomic absorption spectroscopy (AAS) in serum and urine.
Number of subjects: 34
Study 10583708 — intervention group
Group type: EXPERIMENTAL
Intervention: Femur Mg concentration measured by AAS.
Number of subjects: 34
Study 10583708 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of femur Mg concentration and %Ret.
Number of subjects: 34
Study 8561763 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive treatment
Number of subjects: 74
Study 8561763 — intervention group
Group type: COMPARATOR
Intervention: Behavioral treatment
Number of subjects: 74
Study 1796932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiary care facilities
Number of subjects: 74
Study 1796932 — intervention group
Group type: COMPARATOR
Intervention: Nontertiary care facilities
Number of subjects: 74
Study 6198313 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation followed by chemotherapy (sequential)
Number of subjects: 65
Study 6198313 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with temporary interruption for radiation (sandwich)
Number of subjects: 65
Study 30773722 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-supplemented yogurt drink (300 IU day-1)
Number of subjects: 416
Study 30773722 — intervention group
Group type: COMPARATOR
Intervention: Plain yogurt drink (placebo group)
Number of subjects: 416
Study 29504498 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled glucocorticoids (fluticasone at a dose of 220 μg per inhalation, two inhalations twice daily) for 7 days at early signs of loss of asthma control.
Number of subjects: 254
Study 29504498 — intervention group
Group type: COMPARATOR
Intervention: Low-dose inhaled glucocorticoids (fluticasone propionate at a dose of 44 μg per inhalation, two inhalations twice daily) continued.
Number of subjects: 254
Study 26474541 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant sites with <2 mm of keratinized mucosa (Narrow Group)
Number of subjects: 80
Study 26474541 — intervention group
Group type: COMPARATOR
Intervention: Implant sites with ≥2 mm of keratinized mucosa (Wide Group)
Number of subjects: 80
Study 23883550 — intervention group
Group type: EXPERIMENTAL
Intervention: One-question screener
Number of subjects: 59
Study 23883550 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-item FFQ
Number of subjects: 59
Study 23883550 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirty-six-item fish questionnaire
Number of subjects: 59
Study 23883550 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all methods
Number of subjects: 59
Study 23634566 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-erect position (Group A)
Number of subjects: 76
Study 23634566 — intervention group
Group type: COMPARATOR
Intervention: Supine position (Group B, Control)
Number of subjects: 76
Study 18692428 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation
Number of subjects: 45
Study 17463113 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps-sparing technique
Number of subjects: 120
Study 17463113 — intervention group
Group type: COMPARATOR
Intervention: Standard arthrotomy
Number of subjects: 120
Study 15139955 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser application (809 nm, 140 mJ, 50 Hz, Ø 600 micro m fibre, contact mode, absorber, 1 min)
Number of subjects: 80
Study 15139955 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluoride varnish (0.1 mg, Duraphat) for 6 h
Number of subjects: 80
Study 15139955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined application of laser and fluoride varnish
Number of subjects: 80
Study 15139955 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 80
Study 11374763 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile (AN69) membrane (n = 19)
Number of subjects: 42
Study 11374763 — intervention group
Group type: COMPARATOR
Intervention: Cellulose acetate (CA) membrane (n = 23)
Number of subjects: 42
Study 9589293 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g mesalamine enema
Number of subjects: 287
Study 9589293 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g mesalamine enema
Number of subjects: 287
Study 9589293 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g mesalamine enema
Number of subjects: 287
Study 9589293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 8060581 — intervention group
Group type: EXPERIMENTAL
Intervention: High NaCl diet (342 mmol/day)
Number of subjects: 31
Study 8060581 — intervention group
Group type: COMPARATOR
Intervention: Low NaCl diet (34 mmol/day)
Number of subjects: 31
Study 2972628 — intervention group
Group type: EXPERIMENTAL
Intervention: Short interval regimen (10 micrograms of Merck Sharp & Dohme recombinant HB vaccine at 0, 2, and 6 weeks)
Number of subjects: 53
Study 2972628 — intervention group
Group type: COMPARATOR
Intervention: Recommended interval regimen (0, 1, and 6 months)
Number of subjects: 53
Study 29751850 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization exercises on the transversus abdominis and lumbar multifidus muscles
Number of subjects: 29
Study 29751850 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 29
Study 28247490 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week school-based educational preventive programme
Number of subjects: 401
Study 26648712 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (continuous and interval sessions)
Number of subjects: 16
Study 26648712 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 16
Study 23146293 — intervention group
Group type: EXPERIMENTAL
Intervention: ranolazine, 375 mg bid for 3 weeks (group 1)
Number of subjects: 30
Study 23146293 — intervention group
Group type: EXPERIMENTAL
Intervention: ranolazine, 375 mg bid for 2 weeks, followed by placebo bid for 1 week (group 2)
Number of subjects: 30
Study 23146293 — intervention group
Group type: COMPARATOR
Intervention: placebo bid for 3 weeks (group 3)
Number of subjects: 30
Study 21946094 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative acceleromyography monitoring
Number of subjects: 155
Study 21946094 — intervention group
Group type: COMPARATOR
Intervention: Conventional qualitative train-of-four monitoring
Number of subjects: 155
Study 19364687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3) 50,000 units weekly for 8 weeks
Number of subjects: 100
Study 19364687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19364687 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely deficient patients (25[OH]D <10 ng/mL) treated in an unblinded fashion
Number of subjects: 100
Study 16129567 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral risk-reduction intervention trial
Number of subjects: 598
Study 15242697 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 35
Study 15242697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11095487 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (Premarin), 0.625 mg/day
Number of subjects: 10
Study 11095487 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene, 60 mg/day
Number of subjects: 10
Study 11095487 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment for 4 weeks)
Number of subjects: 10
Study 9050018 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (i.v. infusion at doses of 10-160 ng/kg/min)
Number of subjects: 2
Study 9050018 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (i.v. infusion)
Number of subjects: 2
Study 9050018 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyramine (i.v. infusion at doses of 5-20 micrograms/kg/min)
Number of subjects: 2
Study 9050018 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyramine (i.v. infusion)
Number of subjects: 2
Study 9050018 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (1.5 micrograms/kg i.v. loading dose followed by 0.15 microgram/kg/min i.v. infusion)
Number of subjects: 2
Study 9050018 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin (2 mg p.o.)
Number of subjects: 2
Study 9050018 — intervention group
Group type: COMPARATOR
Intervention: Yohimbine (15 mg p.o.)
Number of subjects: 2
Study 9050018 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol (15 mg p.o.)
Number of subjects: 2
Study 8189112 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 11712
Study 3522114 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver acetate chewing gum
Number of subjects: 282
Study 3522114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 28777054 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-only group (n = 20)
Number of subjects: 78
Study 28777054 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression and exercise group (n = 20)
Number of subjects: 78
Study 28777054 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 78
Study 28777054 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy group (n = 20)
Number of subjects: 78
Study 27087510 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative point‐of‐care device screening for hCGβcf concentrations
Number of subjects: 100
Study 27087510 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantification of intact hCG, hCGβcf, hCGβ, and specific gravity
Number of subjects: 100
Study 27087510 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of specific gravity with intact hCG, hCGβ, and hCGβcf
Number of subjects: 100
Study 27087510 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of hCGβcf concentrations during gestation
Number of subjects: 100
Study 27087510 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of individual patterns of hCGβcf excretion
Number of subjects: 100
Study 24292894 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 15
Study 24292894 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline aggression
Number of subjects: 15
Study 24292894 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced physiological responsiveness/lower electrodermal reactivity to ATD
Number of subjects: 15
Study 22644646 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-management (IBSM)
Number of subjects: 90
Study 22644646 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 90
Study 20637377 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT+ (procalcitonin result revealed to the attending physician)
Number of subjects: 384
Study 20637377 — intervention group
Group type: COMPARATOR
Intervention: PCT- (procalcitonin result not revealed)
Number of subjects: 384
Study 20637377 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT strategy to treat all patients with PCT of 0.5 ng/mL or greater
Number of subjects: 384
Study 16703004 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 96 mg/day
Number of subjects: 646
Study 16703004 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 192 mg/day
Number of subjects: 646
Study 16703004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 646
Study 15849470 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent laparoscopic cholecystectomy (ULC)
Number of subjects: 75
Study 15849470 — intervention group
Group type: COMPARATOR
Intervention: Elective laparoscopic cholecystectomy (ELC)
Number of subjects: 75
Study 11991610 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy (5 MU interferon-alpha2b daily for 4 weeks followed by 5 MU TIW for 44 weeks)
Number of subjects: 135
Study 11991610 — intervention group
Group type: COMPARATOR
Intervention: Noninduction therapy (5 MU interferon-alpha2b TIW for 48 weeks)
Number of subjects: 135
Study 11991610 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 135
Study 11991610 — intervention group
Group type: COMPARATOR
Intervention: Noninduction therapy
Number of subjects: 135
Study 10207209 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric in-patient rehabilitation
Number of subjects: 55
Study 7879724 — intervention group
Group type: EXPERIMENTAL
Intervention: Taped therapeutic suggestions
Number of subjects: 66
Study 7879724 — intervention group
Group type: EXPERIMENTAL
Intervention: Taped music
Number of subjects: 66
Study 7879724 — intervention group
Group type: COMPARATOR
Intervention: Blank tapes (Control)
Number of subjects: 66
Study 2141082 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 1% etidocaine applied to the banded portion of each fallopian tube after laparoscopic tubal ligation
Number of subjects: 0
Study 2141082 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 0
Study 363995 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (20 microgram/kg)
Number of subjects: 43
Study 363995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.20 ml/kg)
Number of subjects: 43
Study 31331574 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a + sesame oil (0.5 ml/kg/day for 6 months)
Number of subjects: 93
Study 31331574 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a (30 μg/week)
Number of subjects: 93
Study 28177744 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot exposure (33 °C)
Number of subjects: 12
Study 28177744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure (7 °C)
Number of subjects: 12
Study 28177744 — intervention group
Group type: COMPARATOR
Intervention: Room temperature exposure (20 °C)
Number of subjects: 12
Study 26370414 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cord clamping (within 20 seconds)
Number of subjects: 0
Study 26370414 — intervention group
Group type: COMPARATOR
Intervention: Deferred cord clamping (after at least 2 minutes)
Number of subjects: 0
Study 24377608 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (multiple approaches including face‐to‐face interviews, telephone counselling, educational materials, group counselling, individual counselling by trained medical social workers)
Number of subjects: 0
Study 24377608 — intervention group
Group type: COMPARATOR
Intervention: Control group (general awareness training on tobacco hazards and anti‐tobacco leaflet)
Number of subjects: 0
Study 24377608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study 24377608 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21286885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (30 patients)
Number of subjects: 60
Study 21286885 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 patients)
Number of subjects: 60
Study 19671933 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 99231
Study 19671933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99231
Study 17152004 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI schedule (IPV at 6, 10, and 14 weeks)
Number of subjects: 455
Study 17152004 — intervention group
Group type: COMPARATOR
Intervention: US schedule (IPV at 2, 4, and 6 months)
Number of subjects: 455
Study 15966502 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 5 mg (CEE/MPA)
Number of subjects: 65
Study 15966502 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 65
Study 12209104 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐mm chambers
Number of subjects: 30
Study 12209104 — intervention group
Group type: COMPARATOR
Intervention: 6‐mm chambers
Number of subjects: 30
Study 10496359 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide 600 mg m(‐2) day 1 and 8 i.v., 5‐fluorouracil 600 mg m(‐2) day 1 and 8 i.v., methotrexate 40 mg m(‐2) day 1 and 8 i.v., monthly for 6 cycles)
Number of subjects: 116
Study 10496359 — intervention group
Group type: COMPARATOR
Intervention: MM (methotrexate 30 mg m(‐2), mitoxantrone 6.5 mg m(‐2), both i.v. day 1 3‐weekly for 8 cycles)
Number of subjects: 116